Tezepelumab versus Dupixent

Quote

anonymous

Guest
Dupixent is a proven blockbuster and it has shown to be very effective for severe asthma patients with no negative trials unlike Teze. Outside of MOA, are there any advantages at all over Dupixent? I’m sure it will be used in the approved indication and will gain some market share, but what will be the main selling points if any? I can’t see this drug gaining much traction.
 

anonymous said:
Dupixent is a proven blockbuster and it has shown to be very effective for severe asthma patients with no negative trials unlike Teze. Outside of MOA, are there any advantages at all over Dupixent? I’m sure it will be used in the approved indication and will gain some market share, but what will be the main selling points if any? I can’t see this drug gaining much traction.
Click to expand...
There’s absolutely zero need for this drug to even launch. Recently crowded market. Brings nothing new. Doctors will use Xolair, Dupi, and even Fasenra, way before this one. Only new scripts will come at expense of Fasenra, it’s own drug.
 
anonymous said:
There’s absolutely zero need for this drug to even launch. Recently crowded market. Brings nothing new. Doctors will use Xolair, Dupi, and even Fasenra, way before this one. Only new scripts will come at expense of Fasenra, it’s own drug.
Click to expand...
Yep... this is just another me-too which Amgen is really good at picking lately. SMH
 
If you don't think teze will bring something new to the market, you clearly are uneducated about this space. Offering Drs the ability to skip having to do biomarker testing will be HUGE. Plus, even if they want to confirm source of inflammation, the teze data is superior to all other currently available products.
 
anonymous said:
Dupixent is a proven blockbuster and it has shown to be very effective for severe asthma patients with no negative trials unlike Teze. Outside of MOA, are there any advantages at all over Dupixent? I’m sure it will be used in the approved indication and will gain some market share, but what will be the main selling points if any? I can’t see this drug gaining much traction.
Click to expand...

Buy and Bill. No bio marker. That’s pretty big. Yes....there will be a question around the OCS trial. Just like there are questions around Dupixent seeing increased eosinophils and the risk of HES is some patients.

You should do more....a lot more....research about the pros and cons of each medicine. If you did you’d understand that there is room for a medicine like teze to solve needs that other meds in the market still struggle with.
 
anonymous said:
If you don't think teze will bring something new to the market, you clearly are uneducated about this space. Offering Drs the ability to skip having to do biomarker testing will be HUGE. Plus, even if they want to confirm source of inflammation, the teze data is superior to all other currently available products.
Click to expand...

There is no Biomarkers required for Dupixent, they have much better OCS Reduction Data than Teze and they have 3 indications with Asthma being the smallest indication of the 3.
 
AZ also has inhaled dupi. Amgen had talk and nothing else

PRS-060 is Pieris’ lead respiratory Anticalin®-based drug candidate, developed in collaboration with AstraZeneca. PRS-060 blocks the IL-4Rα immunoreceptor, inhibiting small IL-4 and IL-3 proteins that drive a cascade of inflammatory responses in the lungs.

The small size and stability of PRS-060 allow the drug to be inhaled directly into the lungs, rather than injected, potentially achieving the same benefits as systemic treatments, but with lower doses and fewer side effects. Phase 1 trials have shown significantly reduced levels of fractional exhaled nitric oxide (FeNO), a biomarker for asthma, in patients with mild asthma.
 
anonymous said:
There is no Biomarkers required for Dupixent, they have much better OCS Reduction Data than Teze and they have 3 indications with Asthma being the smallest indication of the 3.
Click to expand...

For the 90% of patients not dependent on OCS, Dupi absolutely requires a eos count of 150 or higher. That OCS reduction of 28% vs placebo is really impressive, considering both Nucala and Fasenra both show 50% reductions vs placebo.
 
The TSLP MOA will encompass dupi, the IL-5’s and Xolair all in one injection. Being higher up the cascade and being less targeted may be why some of the data isn’t as strong as Dupixent’s but it’s certainly enough to best the IL-5’s & Xolair in the Buy & Bill market. It will just depend on the indication and the safety profile. Then it’s dupi V’s teze and teze is the one they will make money injecting. Dupixent soared last year bc no one wanted to go to the offices to get an injection. That’s why Xolair has been pursuing and just got approved for a patient administered Injection device. Now that COVID is residing, the power of the purse strings is back in the hands of the buy & bill market.
 
anonymous said:
For the 90% of patients not dependent on OCS, Dupi absolutely requires a eos count of 150 or higher. That OCS reduction of 28% vs placebo is really impressive, considering both Nucala and Fasenra both show 50% reductions vs placebo.
Click to expand...

it’s about ease of getting approved the clinical stuff is close enough to compete with what’s on the market. besides this is about exacerbation reduction over ocs reductions!!
 
anonymous said:
The TSLP MOA will encompass dupi, the IL-5’s and Xolair all in one injection. Being higher up the cascade and being less targeted may be why some of the data isn’t as strong as Dupixent’s but it’s certainly enough to best the IL-5’s & Xolair in the Buy & Bill market. It will just depend on the indication and the safety profile. Then it’s dupi V’s teze and teze is the one they will make money injecting. Dupixent soared last year bc no one wanted to go to the offices to get an injection. That’s why Xolair has been pursuing and just got approved for a patient administered Injection device. Now that COVID is residing, the power of the purse strings is back in the hands of the buy & bill market.
Click to expand...

Your statement makes no sense. If Teze encompasses all of the other biologics because of it's MOA wouldn't it be as good or better? Plus, no one will buy and bill Teze at launch because you more than likely will not launch the drug with a specific J Code... no one will do it with a generic J Code because there's to much of a chance they will get burned. The competition (less Dupi) has specific J Codes and they will stick with those options until Amgen gets one assigned.
 
anonymous said:
Your statement makes no sense. If Teze encompasses all of the other biologics because of it's MOA wouldn't it be as good or better? Plus, no one will buy and bill Teze at launch because you more than likely will not launch the drug with a specific J Code... no one will do it with a generic J Code because there's to much of a chance they will get burned. The competition (less Dupi) has specific J Codes and they will stick with those options until Amgen gets one assigned.
Click to expand...

you clearly do t have an understanding of the relative strengths and weaknesses of the MOA story. You are right about the J code at launch....but that’s temporary.
 
anonymous said:
Your statement makes no sense. If Teze encompasses all of the other biologics because of it's MOA wouldn't it be as good or better? Plus, no one will buy and bill Teze at launch because you more than likely will not launch the drug with a specific J Code... no one will do it with a generic J Code because there's to much of a chance they will get burned. The competition (less Dupi) has specific J Codes and they will stick with those options until Amgen gets one assigned.
Click to expand...

who said it wasn’t as good? Do your research and learn how to read a clinical trial... conflicting data on a single endpoint does not make a drug a dud. Just means they need someone who can actually sell it...
 
anonymous said:
who said it wasn’t as good? Do your research and learn how to read a clinical trial... conflicting data on a single endpoint does not make a drug a dud. Just means they need someone who can actually sell it...
Click to expand...
Never said it wasn't as good, just commenting on what the other person said in their post. They said the MOA encompassed all of the other respiratory biologics then contradicted themselves saying the data didn't play out that way.
And the J-code, while temporary, will be important, probably won't happen for a least a quarter or two post launch. Which is lucky, they used to only issue them once a year.
 
anonymous said:
Never said it wasn't as good, just commenting on what the other person said in their post. They said the MOA encompassed all of the other respiratory biologics then contradicted themselves saying the data didn't play out that way.
And the J-code, while temporary, will be important, probably won't happen for a least a quarter or two post launch. Which is lucky, they used to only issue them once a year.
Click to expand...

I stick by my comments on the MOA. Higher up the cascade means less targeted and maybe not as strong but still encompasses all of the other respiratory biologics. Look at Otezla’s MOA for a comparison. Not as strong but significantly better safety profile while covering multiple pathways like IL-17, IL-17A, IL-22, & TNFa. Higher up the pathway.
 
anonymous said:
I stick by my comments on the MOA. Higher up the cascade means less targeted and maybe not as strong but still encompasses all of the other respiratory biologics. Look at Otezla’s MOA for a comparison. Not as strong but significantly better safety profile while covering multiple pathways like IL-17, IL-17A, IL-22, & TNFa. Higher up the pathway.
Click to expand...

17A & 17F*
 


Write your reply...
Top Bottom
Back
Quote